Key Takeaways:
- Alphamab grants Pathos AI exclusive JSKN016 rights outside Greater China for $125 million upfront
- Milestone payments reach $2.093 billion plus tiered royalties on net sales
- Phase III trial for triple-negative breast cancer is underway
戻る
Alphamab licenses JSKN016 to Pathos AI in $2.1 billion deal
Alphamab's $2.1 billion licensing deal hands US biotech Pathos AI exclusive rights to JSKN016, a bispecific antibody-drug conjugate for lung and breast cancer, outside Greater China, in one of the largest cross-border ADC pacts of the year.
The agreement, disclosed in an exchange filing, gives Jiangsu Alphamab Biopharmaceuticals, the company's wholly-owned unit, a non-refundable $125 million upfront payment and up to $2.093 billion in milestone payments, plus tiered royalties in the high single-digit to low double-digit percentages on annual net sales in licensed territories. Pathos AI also granted Alphamab warrants to subscribe for $62.5 million in preferred shares.
JSKN016 is a proprietary bispecific ADC, a class of therapy that pairs an antibody targeting two tumor antigens with a toxic payload delivered directly to cancer cells. The dual-targeting design is meant to improve tumor selectivity and reduce the off-target toxicity that has limited first-generation ADCs. Multiple clinical studies are underway testing the drug as a monotherapy and in combination for lung and breast cancer. A Phase III trial for triple-negative breast cancer is in progress, while a subcutaneous formulation is being studied in a China Phase Ib and an Australia Phase I trial.
The deal de-risks Alphamab's balance sheet, injecting $125 million in cash upfront while the milestone stream funds ongoing trials without diluting shareholders. For Pathos AI, the pact secures a late-stage oncology asset with a Phase III program already running, giving the AI-driven biotech a shot at a market where bispecific ADCs are drawing heavy investment from larger rivals such as Daiichi Sankyo, AstraZeneca and Merck. Alphamab shares trade on the Hong Kong exchange under the ticker 09966.
The transaction shows the flow of Chinese biopharma assets into US hands as AI-focused drug developers seek clinical-stage programs. Alphamab did not disclose a closing date or the specific sales thresholds tied to its milestone payments, and the deal remains subject to customary closing conditions.
This article is for informational purposes only and does not constitute investment advice.
[1] ALPHAMAB-B (09966.HK) Grants Exclusive Development Rights of JSKN016 to Pathos AI in Deal Worth Nearly USD2.1 Billion[2] Curium strikes $8bn deal to buy radiopharma rival Lantheus - pharmaphorum[3] Beyond Annual Physicals: Function Secures $450M Growth Financing from General Catalyst - HIT Consultant[4] Curium strikes up to $8B deal for radiopharma rival Lantheus - Fierce Biotech[5] Pathos AI Enters Global Licensing Agreement with ...
